A synthetic Ala-Glu-Asp tripeptide from the Khavinson bioregulator family studied for cartilage and connective-tissue gene regulation.
Pre-loaded with a typical Cartalax vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Cartalax. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 1 mg – 2 mg | cyclic research schedules (often described as courses rather than indefinite daily use) | subcutaneous or topical research formats | Research-supply and bioregulator protocol discussions (limited Western RCT anchoring) Common secondary references discuss roughly 1–2 mg per administration in research settings; primary dose-ranging RCTs in major English journals remain sparse. |
| 1 mcg – 100 mcg | media exposure per experimental design | in vitro | In vitro / cell-culture bioregulator work Cell studies use concentration-based media spiking rather than injectable mcg charts. |
People searching this page also look for: cartalax peptide dosage, cartalax peptide dosage protocol, cartalax peptide dosage 10 mg 20 days, cartalax peptide dosage instructions, cartalax peptide dosage reddit, cartalax peptide injection dosage.
Cartalax is the synthetic tripeptide alanine-glutamic acid-aspartic acid (AED). It belongs to the ultrashort peptide bioregulator set associated with Vladimir Khavinson’s research program. Investigators study Cartalax for tissue-selective effects on cartilage, chondrocytes, and related connective-tissue cell models.
English-language peer-reviewed coverage is thinner than for major clinical peptides. Available work embeds AED among short peptides that can enter cells, interact with nuclear targets, and modulate gene expression linked to extracellular matrix maintenance and cellular aging phenotypes. Much primary detail still sits in Russian-institute literature and subsequent systematic reviews.
For SEO dosage pages, honesty matters: Cartalax does not have a large Western randomized-dose evidence base. Reported handling ranges below are research-community reference points and review-linked mechanistic context, not clinical prescribing standards. Research use only.
As an ultrashort peptide, AED is investigated for carrier-mediated transport (POT/LAT family discussions appear in Khavinson-linked transport papers) and subsequent nuclear/epigenetic modulation rather than classical long-residence GPCR agonism. In cartilage-oriented models, research interest centers on chondrocyte gene programs, matrix protein expression, and senescence-associated markers. The precise target map is still an active research question.
cartilage and chondrocyte biology · extracellular matrix regulation · ultrashort peptide transport · cellular aging / senescence marker research · Khavinson bioregulator comparative studies
Gerontology institutes, connective-tissue biology labs, and groups mapping ultrashort peptide transport and gene regulation are the core audience. Joint-health product marketers often outrun the peer-reviewed dose literature, so careful researchers separate mechanistic papers from commercial claims.
Lyophilized Cartalax is stored cold, dry, and light-protected. After reconstitution, refrigerate and use within the laboratory’s validated window; avoid freeze-thaw cycling of working solutions when possible.
In bioregulator literature Cartalax is sometimes discussed alongside other tissue-targeted short peptides (for example cartilage complex comparisons or fibroblast-oriented peptides) when researchers map organ-specific cytomedine sets. It may also appear near collagen-support or joint-matrix research tools. Evidence for formal synergistic stacks is limited.
The questions people actually search for, answered plainly.
There is no large, widely replicated Western dose-finding trial series. Research-community materials often mention about 1–2 mg per administration in cyclic protocols. Treat that as a thin secondary reference range, not a validated medical dose.
For a 20 mg lyophilized vial, 2 mL bacteriostatic water yields 1 mg per 0.1 mL, which simplifies 1–2 mg research measurements. Confirm against your label and pipette tolerances.
Secondary bioregulator write-ups sometimes describe daily administrations during short courses, then time off. Primary English dose-frequency standards are not well established.
Any chart should openly state the weak clinical dose literature and distinguish in vitro concentrations from in vivo research handling. Overconfident charts are a red flag for this compound.
Detailed human pharmacokinetic half-life data are sparse in major indexed sources. Ultrashort peptides generally clear quickly; durable claims usually refer to downstream gene-expression effects rather than long plasma residence.
Research discussions sometimes group it with other Khavinson-style bioregulators or matrix-support compounds. Formal controlled stack trials are limited, so combinations remain experimental research questions.
Both parenteral research handling and topical/connective-tissue research formats are discussed in secondary sources. Route should match the specific experimental design and material grade.
No. It is a three-amino-acid synthetic peptide studied for regulatory effects on cartilage-related cells, not a bulk collagen supplement.
Primary literature on Cartalax. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides